Pardes Biosciences has a quick ratio of 81.72. It generally indicates good short-term financial strength.
The historical rank and industry rank for Pardes Biosciences's Quick Ratio or its related term are showing as below:
PRDS'
s Quick Ratio Range Over the Past 10 Years
Min: 4.53 Med: 19.32 Max: 81.72
Current: 81.72
During the past 3 years, Pardes Biosciences's highest Quick Ratio was 81.72. The lowest was 4.53. And the median was 19.32.
PRDS's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.6
vs PRDS: 81.72
Pardes Biosciences Quick Ratio Historical Data
The historical data trend for Pardes Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pardes Biosciences's Quick Ratio
For the Biotechnology subindustry, Pardes Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pardes Biosciences's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Pardes Biosciences's Quick Ratio falls into.
Pardes Biosciences Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Pardes Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pardes Biosciences (NAS:PRDS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Pardes Biosciences Quick Ratio Related Terms
Thank you for viewing the detailed overview of Pardes Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Pardes Biosciences (Pardes Biosciences) Business Description
Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRDS has been successfully added to your 